Participating in Cantor Antibiotics Summit panel

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma to participate in panel discussion at the Cantor Antibiotics Summit

Brighton, United Kingdom - 11 January 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that Dr Bill Love, Chief Scientific Officer and Founder of Destiny Pharma, will participate in the panel discussion titled 'Novel Ways to Treat and/or Address Infections' at the Cantor Antibiotics Summit on Wednesday 17 January 2018 at 12:15pm EST at the Omni Berkshire Hotel, 21 East 52nd Street, New York, NY 10022.

The Cantor Antibiotics Summit, hosted by Cantor Fitzgerald, will bring together leading antibiotic companies to discuss novel ways to treat infections, what will drive the uptake of these new products, and important catalysts to look forward to in 2018.

For further information, please contact:

Destiny Pharma

Neil Clark, CEO

Simon Sacerdoti, CFO

pressoffice@destinypharma.com

+44 (0)1273 704 440

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Hanna Skeppner

destinypharma@fticonsulting.com 

+44 (0) 20 3727 1000

Cantor Fitzgerald Europe (Nominated Adviser and Broker)

Philip Davies / Will Goode, Corporate Finance

pdavies@cantor.co.uk

+44 (0)20 7894 8337

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com